Form 4: Alaunos Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Holger Weis, CEO of Alaunos Therapeutics, Inc., received 23,564 shares of common stock on October 6, 2026.
Summary
- Grant/award: acquired 23,564 Common Stock at $0.74 ($17,541) on October 6, 2026; holds 49,047 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Holger Weis — Officer (CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-06 | Grant/award | Common Stock | 23,564 | $1 | $17.5K | 49,047 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-06 | Grant/award (23,564 shares) |
Keywords
insider transaction, Form 4, TCRT, Alaunos Therapeutics, Inc., neutral, Holger Weis
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.